miR‑331‑3p suppresses cell invasion and migration in colorectal carcinoma by directly targeting NRP2

Zhang,Hongye; Wang,Ruiyu; Wang,Mingxia

doi:10.3892/ol.2019.11029

miR‑331‑3p suppresses cell invasion and migration in colorectal carcinoma by directly targeting NRP2

Authors:
- Hongye Zhang
- Ruiyu Wang
- Mingxia Wang
View Affiliations

Affiliations: Department of Oncology, Linyi Central Hospital, Linyi, Shandong 276400, P.R. China
Published online on: November 1, 2019 https://doi.org/10.3892/ol.2019.11029
Pages: 6501-6508
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal carcinoma (CRC) is a common tumor of the digestive system with poor prognosis. Studies have shown that aberrant microRNA (miRNA) expression can affect CRC progression by regulating target genes. In the present study, we investigated the functional roles and potential mechanisms of miR‑331‑3p in CRC. The expression of miR‑331‑3p and neuropilin‑2 (NRP2) in CRC was detected by RT-qPCR. Then, Transwell assays were conducted to investigate the influence of miR‑331‑3p on CRC cell invasion and migration abilities. Luciferase reporter assays were performed to determine the target gene of miR‑331‑3p. It was found that miR‑331‑3p expression was notably declined in CRC and inversely correlated with the NRP2 expression. miR‑331‑3p upregulation significantly inhibited CRC cell invasion and migration. Additionally, western blot analysis demonstrated that miR‑331‑3p restoration evidently suppressed CRC cell EMT. Moreover, NRP2 was conformed to be a novel target of miR‑331‑3p and knockdown of NRP2 partially inversed the effects of the miR‑331‑3p inhibitor on cell invasion and migration. These results suggested that miR‑331‑3p exerted tumor suppressive roles in CRC by targeting NRP2 and miR‑331‑3p/NRP2 may serve as a potential therapy for CRC.

View Figures

View References

1	Bae JM, Kim JH, Kwak Y, Lee DW, Cha Y, Wen X, Lee TH, Cho NY, Jeong SY, Park KJ, et al: Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system. Br J Cancer. 116:1012–1020. 2017. View Article : Google Scholar : PubMed/NCBI
2	Hadjipetrou A, Anyfantakis D, Galanakis CG, Kastanakis M and Kastanakis S: Colorectal cancer, screening and primary care: A mini literature review. World J Gastroenterol. 23:6049–6058. 2017. View Article : Google Scholar : PubMed/NCBI
3	Haraldsdottir S, Einarsdottir HM, Smaradottir A, Gunnlaugsson A and Halfdanarson TR: Colorectal cancer - review. Laeknabladid. 100:75–82. 2014.(In Icelandic). PubMed/NCBI
4	Lieberman D, Ladabaum U, Cruz-Correa M, Ginsburg C, Inadomi JM, Kim LS, Giardiello FM and Wender RC: Screening for colorectal cancer and evolving issues for physicians and patients: A Review. JAMA. 316:2135–2145. 2016. View Article : Google Scholar : PubMed/NCBI
5	Liu W, Sun Y, Zhang L and Xing BC: Negative surgical margin improved long-term survival of colorectal cancer liver metastases after hepatic resection: A systematic review and meta-analysis. Int J Colorectal Dis. 30:1365–1373. 2015. View Article : Google Scholar : PubMed/NCBI
6	Massat NJ, Moss SM, Halloran SP and Duffy SW: Screening and primary prevention of colorectal cancer: A review of sex-specific and site-specific differences. J Med Screen. 20:125–148. 2013. View Article : Google Scholar : PubMed/NCBI
7	Bonfrate L, Altomare DF, Di Lena M, Travaglio E, Rotelli MT, De Luca A and Portincasa P: MicroRNA in colorectal cancer: New perspectives for diagnosis, prognosis and treatment. J Gastrointestin Liver Dis. 22:311–320. 2013.PubMed/NCBI
8	Karatas OF, Suer I, Yuceturk B, Yilmaz M, Hajiyev Y, Creighton CJ, Ittmann M and Ozen M: The role of miR-145 in stem cell characteristics of human laryngeal squamous cell carcinoma Hep-2 cells. Tumour Biol. 37:4183–4192. 2016. View Article : Google Scholar : PubMed/NCBI
9	Xu L, Li Q, Xu D, Wang Q, An Y, Du Q, Zhang J, Zhu Y and Miao Y: hsa-miR-141 downregulates TM4SF1 to inhibit pancreatic cancer cell invasion and migration. Int J Oncol. 44:459–466. 2014. View Article : Google Scholar : PubMed/NCBI
10	Wang G, Shen N, Cheng L, Lin J and Li K: Downregulation of miR-22 acts as an unfavorable prognostic biomarker in osteosarcoma. Tumour Biol. 36:7891–7895. 2015. View Article : Google Scholar : PubMed/NCBI
11	Bai QL, Hu CW, Wang XR, Shang JX and Yin GF: miR-616 promotes proliferation and inhibits apoptosis in glioma cells by suppressing expression of SOX7 via the Wnt signaling pathway. Eur Rev Med Pharmacol Sci. 21:5630–5637. 2017.PubMed/NCBI
12	Wang Z, Liao H, Deng Z, Yang P, Du N, Zhanng Y and Ren H: miRNA-205 affects infiltration and metastasis of breast cancer. Biochem Biophys Res Commun. 441:139–143. 2013. View Article : Google Scholar : PubMed/NCBI
13	Staton CA, Kumar I, Reed MW and Brown NJ: Neuropilins in physiological and pathological angiogenesis. J Pathol. 212:237–248. 2007. View Article : Google Scholar : PubMed/NCBI
14	Pellet-Many C, Frankel P, Jia H and Zachary I: Neuropilins: Structure, function and role in disease. Biochem J. 411:211–226. 2008. View Article : Google Scholar : PubMed/NCBI
15	Drabkin HA, Starkova J and Gemmill RM: A triad of NRP2, DLX and p53 proteins in lung cancer metastasis. Oncotarget. 8:96464–96465. 2017. View Article : Google Scholar : PubMed/NCBI
16	Fujii T, Shimada K, Asano A, Tatsumi Y, Yamaguchi N, Yamazaki M and Konishi N: MicroRNA-331-3p suppresses cervical cancer cell proliferation and E6/E7 expression by targeting NRP2. Int J Mol Sci. 17:172016. View Article : Google Scholar
17	Yasuoka H, Kodama R, Tsujimoto M, Yoshidome K, Akamatsu H, Nakahara M, Inagaki M, Sanke T and Nakamura Y: Neuropilin-2 expression in breast cancer: Correlation with lymph node metastasis, poor prognosis, and regulation of CXCR4 expression. BMC Cancer. 9:2202009. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta DeltaC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Dweep H, Sticht C, Pandey P and Gretz N: miRWalk - database: Prediction of possible miRNA binding sites by ‘walking’ the genes of three genomes. J Biomed Inform. 44:839–847. 2011. View Article : Google Scholar : PubMed/NCBI
20	Burstein HJ and Schwartz RS: Molecular origins of cancer. N Engl J Med. 358:5272008. View Article : Google Scholar : PubMed/NCBI
21	El Sharawy A, Röder C, Becker T, Habermann JK, Schreiber S, Rosenstiel P and Kalthoff H: Concentration of circulating miRNA-containing particles in serum enhances miRNA detection and reflects CRC tissue-related deregulations. Oncotarget. 7:75353–75365. 2016.PubMed/NCBI
22	Suzuki HI, Katsura A, Matsuyama H and Miyazono K: MicroRNA regulons in tumor microenvironment. Oncogene. 34:3085–3094. 2015. View Article : Google Scholar : PubMed/NCBI
23	Epis MR, Giles KM, Beveridge DJ, Richardson KL, Candy PA, Stuart LM, Bentel J, Cohen RJ and Leedman PJ: miR-331-3p and Aurora kinase inhibitor II co-treatment suppresses prostate cancer tumorigenesis and progression. Oncotarget. 8:55116–55134. 2017. View Article : Google Scholar : PubMed/NCBI
24	Chen L, Chu F, Cao Y, Shao J and Wang F: Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma. Tumour Biol. 36:7439–7447. 2015. View Article : Google Scholar : PubMed/NCBI
25	Cao Y, Zhang J, Xiong D, Wang D, Wu T, Huang A and Tang H: Hsa-miR-331-3p inhibits VHL expression by directly targeting its mRNA 3-UTR in HCC cell lines. Acta Biochim Pol. 62:77–82. 2015. View Article : Google Scholar : PubMed/NCBI
26	Zachary IC, Frankel P, Evans IM and Pellet-Many C: The role of neuropilins in cell signalling. Biochem Soc Trans. 37:1171–1178. 2009. View Article : Google Scholar : PubMed/NCBI
27	Rossignol M, Gagnon ML and Klagsbrun M: Genomic organization of human neuropilin-1 and neuropilin-2 genes: Identification and distribution of splice variants and soluble isoforms. Genomics. 70:211–222. 2000. View Article : Google Scholar : PubMed/NCBI
28	Niland S and Eble JA: Neuropilins in the context of tumor vasculature. Int J Mol Sci. 20:202019. View Article : Google Scholar
29	Favier B, Alam A, Barron P, Bonnin J, Laboudie P, Fons P, Mandron M, Herault JP, Neufeld G, Savi P, et al: Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood. 108:1243–1250. 2006. View Article : Google Scholar : PubMed/NCBI
30	Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003. View Article : Google Scholar : PubMed/NCBI
31	Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK, Kowalski J, Ho C, Reslan HB, Ross J, et al: Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell. 13:331–342. 2008. View Article : Google Scholar : PubMed/NCBI
32	Fung TM, Ng KY, Tong M, Chen JN, Chai S, Chan KT, Law S, Lee NP, Choi MY, Li B, et al: Neuropilin-2 promotes tumourigenicity and metastasis in oesophageal squamous cell carcinoma through ERK-MAPK-ETV4-MMP-E-cadherin deregulation. J Pathol. 239:309–319. 2016. View Article : Google Scholar : PubMed/NCBI
33	Dallas NA, Gray MJ, Xia L, Fan F, van Buren G II, Gaur P, Samuel S, Lim SJ, Arumugam T, Ramachandran V, et al: Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma. Clin Cancer Res. 14:8052–8060. 2008. View Article : Google Scholar : PubMed/NCBI
34	Moriarty WF, Kim E, Gerber SA, Hammers H and Alani RM: Neuropilin-2 promotes melanoma growth and progression in vivo. Melanoma Res. 26:321–328. 2016. View Article : Google Scholar : PubMed/NCBI